Nuclear Receptor Co-Repressor 2

• 

  Subject Areas on Research

  • Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. 
  • Association of Forced Vital Capacity with the Developmental Gene NCOR2. 
  • Corepressor SMRT promotes oxidative phosphorylation in adipose tissue and protects against diet-induced obesity and insulin resistance. 
  • Expression and hormonal regulation of coactivator and corepressor genes. 
  • Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma. 
  • Identification and characterization of a functional zebrafish smrt corepressor (ncor2). 
  • NCoR1 and SMRT play unique roles in thyroid hormone action in vivo. 
  • Nuclear corepressor SMRT is a strong regulator of body weight independently of its ability to regulate thyroid hormone action. 
  • Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. 
  • SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis. 
  • SMRTER, a Drosophila nuclear receptor coregulator, reveals that EcR-mediated repression is critical for development. 
  • The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. 
  • The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. 
  • The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. 
  • The transcription factor B-Myb is maintained in an inhibited state in target cells through its interaction with the nuclear corepressors N-CoR and SMRT. 
  • Thyroid hormone receptor repression is linked to type I pneumocyte-associated respiratory distress syndrome. 
  • Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS). 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Duke Innovation & Entrepreneurship